BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36191632)

  • 1. The novel prolyl hydroxylase-2 inhibitor caffeic acid upregulates hypoxia inducible factor and protects against hypoxia.
    Guo Z; Yang Y; Li L; Zhao Q; Li Y; Liu Z; Hao L; Guo B; Diao A
    Eur J Pharmacol; 2022 Nov; 934():175307. PubMed ID: 36191632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of
    Li XY; Wu CH; Yan YJ; Wang DH; Wang MJ; Hou ZW
    Zhongguo Zhen Jiu; 2022 Nov; 42(11):1278-84. PubMed ID: 36397226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-inducible factor prolyl-hydroxylase-2 mediates transforming growth factor beta 1-induced epithelial-mesenchymal transition in renal tubular cells.
    Han WQ; Zhu Q; Hu J; Li PL; Zhang F; Li N
    Biochim Biophys Acta; 2013 Jun; 1833(6):1454-62. PubMed ID: 23466866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
    Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
    BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-21 contributes to renal protection by targeting prolyl hydroxylase domain protein 2 in delayed ischaemic preconditioning.
    Jiao X; Xu X; Fang Y; Zhang H; Liang M; Teng J; Ding X
    Nephrology (Carlton); 2017 May; 22(5):366-373. PubMed ID: 27030384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells.
    Spinella F; Rosanò L; Del Duca M; Di Castro V; Nicotra MR; Natali PG; Bagnato A
    PLoS One; 2010 Jun; 5(6):e11241. PubMed ID: 20574527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-inducible factor prolyl-hydroxylase 2 senses high-salt intake to increase hypoxia inducible factor 1alpha levels in the renal medulla.
    Wang Z; Zhu Q; Xia M; Li PL; Hinton SJ; Li N
    Hypertension; 2010 May; 55(5):1129-36. PubMed ID: 20308610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetrahydropyridin-4-ylpicolinoylglycines as novel and orally active prolyl hydroxylase 2 (PHD2) inhibitors for the treatment of renal anemia.
    Su K; Li Z; Zhang L; Fang S; Mao M; Sun Z; Zhang X
    Eur J Med Chem; 2022 Aug; 238():114479. PubMed ID: 35675755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuron-specific prolyl-4-hydroxylase domain 2 knockout reduces brain injury after transient cerebral ischemia.
    Kunze R; Zhou W; Veltkamp R; Wielockx B; Breier G; Marti HH
    Stroke; 2012 Oct; 43(10):2748-56. PubMed ID: 22933585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical prolyl hydroxylase domain-2 silencing improves diabetic murine wound closure.
    Wetterau M; George F; Weinstein A; Nguyen PD; Tutela JP; Knobel D; Cohen Ba O; Warren SM; Saadeh PB
    Wound Repair Regen; 2011; 19(4):481-6. PubMed ID: 21627711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production of functional recombinant prolyl hydroxylase-2 enzyme in insect cells for small molecule inhibitor screening studies.
    Guo Z; Zi J; Hao Y; Li Y; Liu Z; Zhao Q; Hao L; Diao A
    Protein Expr Purif; 2022 Jun; 194():106073. PubMed ID: 35192944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Src activates HIF-1α not through direct phosphorylation of HIF-1α specific prolyl-4 hydroxylase 2 but through activation of the NADPH oxidase/Rac pathway.
    Lee HY; Lee T; Lee N; Yang EG; Lee C; Lee J; Moon EY; Ha J; Park H
    Carcinogenesis; 2011 May; 32(5):703-12. PubMed ID: 21335603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transforming growth factor beta1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression.
    McMahon S; Charbonneau M; Grandmont S; Richard DE; Dubois CM
    J Biol Chem; 2006 Aug; 281(34):24171-81. PubMed ID: 16815840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases.
    Marxsen JH; Stengel P; Doege K; Heikkinen P; Jokilehto T; Wagner T; Jelkmann W; Jaakkola P; Metzen E
    Biochem J; 2004 Aug; 381(Pt 3):761-7. PubMed ID: 15104534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury.
    Natarajan R; Salloum FN; Fisher BJ; Kukreja RC; Fowler AA
    Circ Res; 2006 Jan; 98(1):133-40. PubMed ID: 16306444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolyl hydroxylase domain 2 protein suppresses hypoxia-induced endothelial cell proliferation.
    Takeda K; Fong GH
    Hypertension; 2007 Jan; 49(1):178-84. PubMed ID: 17101841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolyl hydroxylase 2 deficiency limits proliferation of vascular smooth muscle cells by hypoxia-inducible factor-1{alpha}-dependent mechanisms.
    Schultz K; Murthy V; Tatro JB; Beasley D
    Am J Physiol Lung Cell Mol Physiol; 2009 Jun; 296(6):L921-7. PubMed ID: 19304911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid degradation of hypoxia-inducible factor-1alpha by KRH102053, a new activator of prolyl hydroxylase 2.
    Choi HJ; Song BJ; Gong YD; Gwak WJ; Soh Y
    Br J Pharmacol; 2008 May; 154(1):114-25. PubMed ID: 18332861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Endothelial PHD2 Suppresses Post-Ischemic Kidney Inflammation through Hypoxia-Inducible Factor-1.
    Rajendran G; Schonfeld MP; Tiwari R; Huang S; Torosyan R; Fields T; Park J; Susztak K; Kapitsinou PP
    J Am Soc Nephrol; 2020 Mar; 31(3):501-516. PubMed ID: 31996410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of angiogenesis through stabilization of hypoxia-inducible factor-1 by silencing prolyl hydroxylase domain-2 gene.
    Wu S; Nishiyama N; Kano MR; Morishita Y; Miyazono K; Itaka K; Chung UI; Kataoka K
    Mol Ther; 2008 Jul; 16(7):1227-34. PubMed ID: 18500250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.